Findings

What do systematic reviews say?

16 questions · 18 findings · 7 reviews · Urology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 11 · 61.1%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 6 · 33.3%High 1 · 5.6%

Desmopressin vs alpha‐blocker

Quality of life

1 finding from 1 review

Desmopressin for treating nocturia in men 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 31 participants
Moderate

Desmopressin plus alpha‐blocker vs alpha‐blocker

Quality of life

1 finding from 1 review

Desmopressin for treating nocturia in men 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 341 participants
Moderate

Desmopressin vs behaviour modifications

Quality of life ‐ not reported

The review found no eligible studies for this question.

1 finding from 1 review

Desmopressin for treating nocturia in men 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Desmopressin vs placebo

Quality of life ‐ not reported

The review found no eligible studies for this question.

2 findings from 1 review

Desmopressin for treating nocturia in men 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Desmopressin for treating nocturia in men 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Desmopressin plus alpha‐blocker vs alpha‐blocker plus anticholinergic

Quality of life ‐ not reported

The review found no eligible studies for this question.

1 finding from 1 review

Desmopressin for treating nocturia in men 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Quality of life (QoL) We reported this outcome narratively in this review. Here, long‐term results (i.e., at the end of treatment) are presented. In the comparison PAZ versus SUN, QoL was measured using FACIT‐F (score range 0‐52; higher scores rep... · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy

The review found no eligible studies for this question.

1 finding from 1 review

First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Single‐dose, preoperative MMC‐EMDA vs single‐dose, postoperative MMC‐PD

Disease‐specific quality of life ‐ not reported

The review found no eligible studies for this question.

1 finding from 1 review

Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Single‐dose, preoperative MMC‐EMDA vs TURBT alone

Disease‐specific quality of life ‐ not reported

The review found no eligible studies for this question.

1 finding from 1 review

Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Degarelix vs standard androgen suppression therapy

Quality of life · hormone‐sensitive prostate cancer

1 finding from 1 review

Degarelix for treating advanced hormone‐sensitive prostate cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 2887 participants
Moderate

Interferon‐α alone vs interferon‐α plus bevacizumab

Quality of life · previously untreated patients with mRCC

The review found no eligible studies for this question.

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Interferon‐α plus bevacizumab vs standard targeted therapies

Quality of life · previously untreated patients with mRCC

The review found no eligible studies for this question.

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Vaccine treatment vs standard therapies

Quality of life · previously untreated patients with mRCC

The review found no eligible studies for this question.

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Interferon‐α combined with targeted therapies vs standard targeted therapies

Quality of life · previously untreated patients with mRCC

The review found no eligible studies for this question.

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pazopanib vs placebo (targeted agent versus placebo)

Health‐related quality of life · Previous treated and treatment‐naïve (54%) metastatic renal cell carcinoma (clear cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 300 participants
High

Early vs deferred AST

Global quality of life · advanced hormone‐sensitive prostate cancer

1 finding from 1 review

Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 285 participants
Moderate

Targeted immunotherapy alone vs standard targeted therapies

Quality of life: improved to an important degree · previously treated patients with mRCC

Targeted immunotherapy alone probably leads to higher quality of life: Clinically relevant improvement in FKSI‐DRS compared with standard targeted therapies (moderate certainty).

2 findings from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 1.51 [1.28, 1.78]
1 study · 704 participants
Moderate
Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 1.37
1 study · 703 participants
Moderate